

Ophthalmology Intra-Vitreous Treatments

Reference Number: F4662
Date of Response: 9th June 2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

1. How many patients over the last 4 months (January to April 2022) have received the following anti-VEGF treatments for any eye condition:

- Aflibercept – **1,231 Patients**
- Brolucizumab – **0 Patients**
- Dexamethasone – **42 Patients**
- Ranibizumab – **74 Patients**

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- Aflibercept – **231 Patients**
- Brolucizumab – **0 Patients**
- Dexamethasone – **10 Patients**
- Ranibizumab – **8 Patients**

In accordance with section 40 (2) of the Freedom of Information Act 2000, We are unable to provide the figures for the following treatment for questions 1 and 2:

- **Bevacizumab**

We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated using the above is less than five. Releasing this data could risk the identification of these patients. This would breach Caldicott principles and principle One of the GDPR.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

3. Please provide the number of patients treated for Diabetic Macular Oedema (DMO) ONLY in the last 4 months (January to April 2022) with the following:

- Aflibercept – **The Trust does not hold this data. Indication was not recorded for any of the patients who were administered this drug.**
- Bevacizumab - **The Trust does not hold this data. Indication was not recorded for any of the patients who were administered this drug.**
- Dexamethasone – **14 Patients**
- Ranibizumab - **The Trust does not hold this data. Indication was not recorded for any of the patients who were administered this drug.**

4. Please provide the number of patients treated for Retinal Vein Occlusion (RVO) ONLY in the last 4 months (January to April 2022) with the following:

- Aflibercept - **The Trust does not hold this data. Indication was not recorded for any of the patients who were administered this drug.**
- Bevacizumab - **The Trust does not hold this data. Indication was not recorded for any of the patients who were administered this drug.**
- Dexamethasone – **29 Patients**
- Ranibizumab - **The Trust does not hold this data. Indication was not recorded for any of the patients who were administered this drug.**